[Primary superficial bladder carcinoma. Prognostic factors for recurrence].

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• Superficial bladder carcinoma necessitates effective management strategies to minimize tumor recurrence.
• Transurethral resection (TUR) is a primary treatment, but recurrence rates remain a concern.
• Prophylactic intravesical chemotherapy is often employed post-TUR to reduce recurrence risk.

Purpose of the Study:

• To identify prognostic factors influencing tumor recurrence after TUR for primary superficial bladder carcinoma.
• To evaluate the efficacy of different chemoprophylactic agents (thiotepa, adriamycin, cisplatin).
• To develop predictive mathematical models for stratifying recurrence risk.

Main Methods:

• A cohort of 155 patients with primary superficial bladder carcinoma (Ta, T1, Tis) underwent TUR.
• Patients received intravesical chemoprophylaxis with thiotepa, adriamycin, or cisplatin.
• Clinical features and treatment variables were analyzed using multivariant logistic regression to determine prognostic significance.
• Mathematical models were developed based on significant prognostic factors.

Main Results:

• Tumor number, tumor stage, and the type of chemoprophylactic drug utilized were identified as significant prognostic factors for recurrence (p=0.04, 0.04, and 0.008, respectively).
• Thiotepa demonstrated superior control of tumor recurrence compared to other agents.
• Multivariant analysis confirmed the predictive value of these variables.

Conclusions:

• Tumor number, stage, and choice of chemoprophylactic agent are critical determinants of recurrence risk in superficial bladder carcinoma.
• Predictive mathematical models integrating these factors can effectively stratify patients into high, medium, and low risk categories.
• These models can aid in personalized treatment strategies and follow-up protocols for bladder cancer patients.